Primary Biliary Cirrhosis Pipeline 2016 Market Review Report

PUNE, India, August 23, 2016 /PRNewswire/ --

ReportsnReports.com adds "Primary Biliary Cirrhosis - Pipeline Review, H1 2016" to its store providing comprehensive information on the Primary Biliary Cirrhosis , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Primary Biliary Cirrhosis targeted therapeutics development and features dormant and discontinued projects.

Complete report on H1 2016 pipeline review of Primary Biliary Cirrhosis with 26 market data tables and 13 figures, spread across 90 pages is available at http://www.reportsnreports.com/reports/655460-primary-biliary-cirrhosis-pipeline-review-h2-2016.html .

Companies discussed in this Primary Biliary Cirrhosis Pipeline Review, H1 2016 report include AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH, Enanta Pharmaceuticals, Inc., Genextra S.p.a., GenKyoTex S.A., GlaxoSmithKline Plc, MediGene AG, NGM Biopharmaceuticals, Inc., Novartis AG, Shire Plc, TGV-Laboratories and Virobay Inc. Drug Profiles mentioned in this research report are A-4250, budesonide, EDP-305, FFP-104, GKT-831, GSK-2330672, Hep-114, LJN-452, maralixibat chloride, MBX-8025, NGM-282, obeticholic acid, RhuDex and VBY-825.

Primary Biliary Cirrhosis Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.  

The report reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical and Unknown stages are 1, 1, 7, 1, 1, 2 and 1 respectively.

Order a purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=655460 .

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Furthermore, this report also reviews key players involved in Primary Biliary Cirrhosis targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis and reviews pipeline therapeutics for Primary Biliary Cirrhosis by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Primary Biliary Cirrhosis therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Primary Biliary Cirrhosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Primary Biliary Cirrhosis.

Another newly published market research report titled on Charcot-Marie-Tooth Disease - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Charcot-Marie-Tooth Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Charcot-Marie-Tooth Disease and special features on late-stage and discontinued projects. Companies discussed in this research are Acetylon Pharmaceuticals, Inc., Addex Therapeutics Ltd, Affectis Pharmaceuticals AG, Genzyme Corporation, InFlectis BioScience, Lead Discovery Center GmbH, PharmatrophiX, Inc. and Pharnext SAS. Charcot-Marie-Tooth Disease Pipeline market research report of 60 pages is available at http://www.reportsnreports.com/reports/655458-charcot-marie-tooth-disease-pipeline-review-h2-2016.html .

Explore more reports on Pharmaceuticals.

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:  

Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com

Connect With Us on:
Facebook:https://www.facebook.com/ReportsnReports/
LinkedIn: https://www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml